Komori
Occurring Fact4888STELLA PHARMA CORPORATIONPharmaceuticals

(Correction) Notice Regarding the Recording of Non-Operating Expenses and Differences Between the Earnings Forecast and Actual Results

The table for the fiscal year ending March 2026 was corrected from “Revision of Earnings Forecast for the Fiscal Year Ended March 2025” to “Difference Between the Earnings Forecast and Actual Results for the Fiscal Year Ending March 2026,” and column B was changed from “Revised Forecast” to “Actual Results.” The figures themselves remain unchanged; the unit display and reference fiscal year have also been corrected.

Worth reading
27Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

What was corrected and how

A subsequent correction by the company to the contents of an already published filing.

Original disclosure13 May 2026

Notice Regarding the Recognition of Non-operating Expenses and Differences Between Forecast and Actual Results

Open the original document
1 dayThe pre-correction wording stayed published for this period (Calculated from the Original Disclosure Date Indicated in the Document)
This correction2026-05-14
Location of correction (where in the original document)

2. Revision of Earnings Forecast ① Difference Between the Earnings Forecast Announced on 14 October 2025 and Actual Results (Fiscal Year Ending March 2026)

Before correction

Headline Revision of Earnings Forecast for the Fiscal Year Ended March 2025 (1 April 2025 to 31 March 2026) / Current Column Heading Revised Forecast (B) / Net Sales 323 / Operating profit △748 / Ordinary income △778 / Net income for the current fiscal year △780 / Net income per share △22.95 / Reference Actual Results for the Previous Fiscal Year (Fiscal Year Ending March 2026)

After correction

Headline Difference Between the Earnings Forecast and Actual Results for the Fiscal Year Ending March 2026 (1 April 2025 to 31 March 2026) / Current Column Heading Actual Results (B) / Net Sales 323 / Operating profit △748 / Ordinary income △778 / Net income for the current fiscal year △780 / Net income per share △22.95 / Reference Fiscal year ended March 2025

ChangesNet Sales △53 / Operating profit 173 / Ordinary income 130 / Net income for the current fiscal year 130 / Net income per share 3.85
Reason for correction

Because part of the information was incorrect

What was corrected and how
ItemDetails
Disclosure subject to correctionNotice Regarding the Recognition of Non-operating Expenses and Differences Between Forecast and Actual Results
Original disclosure date13 May 2026
Location of correction2. Revision of Earnings Forecast ① Difference Between the Earnings Forecast Announced on 14 October 2025 and Actual Results (Fiscal Year Ending March 2026)
Details of correctionHeadline Revision of Earnings Forecast for the Fiscal Year Ended March 2025 (1 April 2025 to 31 March 2026) / Current Column Heading Revised Forecast (B) / Net Sales 323 / Operating profit △748 / Ordinary income △778 / Net income for the current fiscal year △780 / Net income per share △22.95 / Reference Actual Results for the Previous Fiscal Year (Fiscal Year Ending March 2026) → Headline Difference Between the Earnings Forecast and Actual Results for the Fiscal Year Ending March 2026 (1 April 2025 to 31 March 2026) / Current Column Heading Actual Results (B) / Net Sales 323 / Operating profit △748 / Ordinary income △778 / Net income for the current fiscal year △780 / Net income per share △22.95 / Reference Fiscal year ended March 2025(Net Sales △14.2 / Operating profit Not disclosed / Ordinary income Not disclosed / Net income for the current fiscal year Not disclosed / Net income per share Not disclosed)
Reason for correctionBecause part of the information was incorrect
Items this document does not state (1)
Impact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because certain information in the disclosure document published on 13 May 2026 was incorrect.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
(Correction) Notice Regarding the Recording of Non-Operating Expenses and Differences Between the Earnings Forecast and Actual Results | STELLA PHARMA CORPORATION (4888) timely disclosure | Komori